Crenolanib is being evaluated in two phase 3 studies, including in combination with chemotherapy in patients with relapsed/refractory AML and FLT3 mutations (NCT02298166) and in a randomized, head-to-head study of crenolanib vs. midostaurin in combination with standard first-line treatment for AML (NCT03258931). Here, FLT3 is linked to acute myeloid leukemia.